CytaCoat proprietary technology repels bacteria from the surface of medical devices
Offering unique clinical advantages:
No similarity to existing antibiotics or silver based coating technology
– Virgin antimicrobial effect
Covalent coupling, stable effect, not based on leakage of an active substance
– Less likely to promote development of bacterial resistance
Broad antimicrobial spectra
– Including multi-resistant bacterial strains (MRSA, ESBL)
Non-toxic, no adverse reaction upon implantation
– Invasive and non-invasive medical devices
Dipping protocol developed for the coating of medical devices
– Easy and cost-effective to manufacture
– No specific waste disposal problems
CytaCoat competing solutions
Several strategies have been developed and are currently being employed for inhibiting bacterial adherence on medical devices surfaces to prevent biofilm formation.
The use of silver (and similar) agents: Creating a surface that will release free metal ions such as Ag+, Cu2+, Zn2+ or Ni2+ to inhibit the microbial growth. Prolonged use may cause accumulation of these elements in the patient’s body and potential toxicity. The antibacterial effect is being questioned.
Antimicrobial substances: Soaking the surface of the device with antimicrobial substances, which are slowly released, will create a high local dose of the drug on the patient’s body. This makes it possible for bacteria to develop resistance.
CytaCoat’s technology contains only non-toxic, biocompatible organic components forming a structure which is covalently bound to the surface of the device. This impedes microbial colonisation without releasing components into the patient’s body. For this reason, bacteria are not likely to develop resistance to the CytaCoat technology.
The CytaCoat technology excels over competing solutions
CytaCoat has been tested on most common polymer materials used in medical devices